Brain-Risk

Jeffrey Taubenberger, Acting NIAID Director, with laboratory research materials

Intranasal Vaccine Brain Risk: The 2026 BPL-1357 Policy Playing Out

The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins …

Read More →